ClinicalTrials.gg
CompletedNCT04319198Updated Sep 30, 2025Results posted

Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

A Phase 4 interventional study of Sacituzumab Govitecan-hiy in Metastatic Solid Tumors, sponsored by Gilead Sciences. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).

Read the detailed description

This is a rollover study. Only participants who continue to receive clinical benefit from continuation of SG therapy and are tolerating therapy at the time of enrollment are eligible for this study. Participants enrolled may continue to receive SG at the dose that they were receiving in the Gilead parent study at the time of consenting to participate in this rollover study.

02

Conditions studied

  • Metastatic Solid Tumors

Keywords

  • ADC
  • Antibody-Drug Conjugate
  • Trop-2
  • SN-38
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Receiving ongoing treatment with sacituzumab govitecan in a Gilead (previously Immunomedics)-sponsored parent study.
  • Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy.

Key Exclusion Criteria:

  • Females who are pregnant or lactating.
  • Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the parent study in which they participated.
  • Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy.
  • Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)

    All participants who previously received SG in the parent study (IMMU-132-01) will continue to receive the same dose of SG up to a maximum of 10 mg/kg, on Days 1 and 8 of 21-day cycle until progressive disease (PD), toxicity, withdrawal of consent, lost to follow-up or loss of clinical benefit, or sponsor termination of the study was documented and were followed for long-term safety up to maximum 3.9 years.

    Drug: Sacituzumab Govitecan-hiy

  • Experimental
    Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)

    All participants who previously received SG in the parent study (IMMU-132-05) will continue to receive the same dose of SG up to a maximum of 10 mg/kg, on Days 1 and 8 of 21-day cycle until PD, toxicity, withdrawal of consent, lost to follow-up or loss of clinical benefit, or sponsor termination of the study was documented and were followed for long-term safety up to maximum 3.9 years.

    Drug: Sacituzumab Govitecan-hiy

  • Experimental
    Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)

    All participants who previously received SG in the parent study (IMMU-132-15) will continue to receive the same dose of SG up to a maximum of 10 mg/kg, on Days 1 and 8 of 21-day cycle until PD, toxicity, withdrawal of consent, lost to follow-up or loss of clinical benefit, or sponsor termination of the study was documented and were followed for long-term safety up to maximum 3.9 years.

    Drug: Sacituzumab Govitecan-hiy

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Any Adverse Events

    An adverse event was defined as any untoward medical occurrence in a participant administered a medicinal product that does not necessarily have a causal relationship with this treatment.

    Time frame: First dose date up to 30 days post last dose (Up to 3.9 years)

  2. Percentage of Participants Experiencing Any Serious Adverse Events

    A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, was fatal (resulting in death), was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.

    Time frame: First dose date up to 30 days post last dose (Up to 3.9 years)

  3. Percentage of Participants Experiencing Any Grade and Grade 3 or 4 Laboratory Abnormalities

    The percentage of participants experiencing any clinically significant laboratory abnormality was summarized.

    Time frame: First dose date up to 30 days post last dose (Up to 3.9 years)

07

Results

Posted Sep 30, 2025

Participant flow

Participants were enrolled at study sites in the United States, Belgium and France.

Participant flow — Overall Study
MilestoneSacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)
Started31012
Completed000
Not completed31012
Withdrew: Adverse events resolution or stabilization340
Withdrew: Death033
Withdrew: Reason not specified024
Withdrew: Withdrawal of consent005
Withdrew: Site terminated by sponsor010

Outcome measures

PrimaryPercentage of Participants Experiencing Any Adverse Events

An adverse event was defined as any untoward medical occurrence in a participant administered a medicinal product that does not necessarily have a causal relationship with this treatment.

Time frame:
First dose date up to 30 days post last dose (Up to 3.9 years)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Adverse Events
percentage of participantsSacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)
Percentage of Participants Experiencing Any Adverse Events66.7100.091.7
PrimaryPercentage of Participants Experiencing Any Serious Adverse Events

A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, was fatal (resulting in death), was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.

Time frame:
First dose date up to 30 days post last dose (Up to 3.9 years)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Serious Adverse Events
percentage of participantsSacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)
Percentage of Participants Experiencing Any Serious Adverse Events040.08.3
PrimaryPercentage of Participants Experiencing Any Grade and Grade 3 or 4 Laboratory Abnormalities

The percentage of participants experiencing any clinically significant laboratory abnormality was summarized.

Time frame:
First dose date up to 30 days post last dose (Up to 3.9 years)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Any Grade and Grade 3 or 4 Laboratory Abnormalities
percentage of participantsSacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)
Any Grade 1 or Higher Laboratory Abnormalities100.088.981.8
Grade 3 or 4 Laboratory Abnormalities33.344.472.7

Adverse events

Collected over Up to 3.9 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)0/3 (0%)0/3 (0%)2/3 (66.7%)
Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)3/10 (30%)4/10 (40%)10/10 (100%)
Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)3/12 (25%)1/12 (8.3%)11/12 (91.7%)
Most frequent serious events
Most frequent serious events
EventSacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)
ColitisGastrointestinal disorders0/31/100/12
Chest painGeneral disorders0/31/100/12
Covid-19Infections and infestations0/31/100/12
Upper respiratory tract infectionInfections and infestations0/31/100/12
LymphoedemaVascular disorders0/31/100/12
Abdominal painGastrointestinal disorders0/30/101/12
Upper gastrointestinal haemorrhageGastrointestinal disorders0/30/101/12
HiccupsRespiratory, thoracic and mediastinal disorders0/30/101/12
Most frequent other events
Showing 10 of 138
Most frequent other events
EventSacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)
NeutropeniaBlood and lymphatic system disorders2/34/104/12
DiarrhoeaGastrointestinal disorders1/36/102/12
NauseaGastrointestinal disorders0/36/103/12
AnaemiaBlood and lymphatic system disorders1/34/102/12
Abdominal painGastrointestinal disorders0/34/103/12
FatigueGeneral disorders0/34/102/12
HeadacheNervous system disorders0/34/100/12
Ventricular extrasystolesCardiac disorders1/30/100/12
Haemorrhoidal haemorrhageGastrointestinal disorders1/30/100/12
Urinary tract infectionInfections and infestations1/31/100/12

Baseline characteristics

All Treated Participants Analysis Set included all participants who received ≥ 1 dose of study drug following enrollment into this rollover IMMU-132-14 study.

Age, Categorical
Age, Categorical(Participants)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)Total
<=18 years0000
Between 18 and 65 years081018
>=65 years3227
Age, Continuous
Age, Continuous(years)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)Total
Mean71 ± 5.761 ± 10.449 ± 15.556 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)Total
Female310821
Male0044
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)Total
Hispanic or Latino0033
Not Hispanic or Latino310821
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)Total
American Indian or Alaska Native0011
Asian0202
Native Hawaiian or Other Pacific Islander0000
Black or African American0112
White37919
More than one race0011
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-01)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-05)Sacituzumab Govitecan-hziy (Parent Study: IMMU-132-15)Total
Belgium0202
United States371222
France0101
08

Study locations

21 sites
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Rocky Mountain Cancer Center
    Aurora, Colorado 80012, United States
  • Christiana Care Health Services, Christiana Hospital
    Newark, Delaware 19718, United States
  • Florida Cancer Specialists & Research Institute
    Fort Myers, Florida 33905, United States
  • Baptist Health - Miami Cancer Institute
    Miami, Florida 33176, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • University of MD Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • New York Cancer & Blood Specialists - Setauket Medical Oncology
    Port Jefferson, New York 11776, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15213, United States
  • Next Oncology
    Austin, Texas 78758, United States
  • Oncology Consultants,P.A.
    Houston, Texas 77024, United States
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • NEXT Oncology
    San Antonio, Texas 78229, United States
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • CHU UCL NAMUR - Sainte Elisabeth
    Namur, 5000, Belgium
  • Institut Bergonie
    Bordeaux, 33076, France
  • Centre Leon Berard
    Lyon, 69373, France
  • Institut Claudius Regaud
    Toulouse, 31059, France
09

References and documents

Publications

  • Kwapisz D. Sacituzumab Govitecan-hziy in Breast Cancer. Am J Clin Oncol. 2022 Jul 1;45(7):279-285. doi: 10.1097/COC.0000000000000919. Epub 2022 May 12. PubMed 35728046 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Oct 2024, 50 months.

Results were first posted in Sep 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2020
First posted
Mar 24, 2020
StartActual
Aug 4, 2020
Primary completionActual
Oct 18, 2024
CompletionActual
Oct 18, 2024
Results first posted
Sep 30, 2025
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04319198
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 24, 2020
Start date
Aug 4, 2020
Primary completion
Oct 18, 2024
Completion
Oct 18, 2024
Results posted
Sep 30, 2025
Last update
Sep 30, 2025

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion